<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01772290</url>
  </required_header>
  <id_info>
    <org_study_id>GP28465</org_study_id>
    <nct_id>NCT01772290</nct_id>
  </id_info>
  <brief_title>A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib</brief_title>
  <official_title>A Clinical Drug-Drug Interaction Study to Evaluate the Effect of a Proton Pump Inhibitor, a Combined P-gp/CYP3A4 Inhibitor, and a CYP2C9 Inhibitor on the Pharmacokinetics of Vismodegib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This randomized, open-label, 4-arm, multiple-dose study will evaluate the effect of&#xD;
      coadministration of a protein pump inhibitor, an inhibitor of P-glycoprotein and CYP3A4, or&#xD;
      an inhibitor of CYP2C9 on the pharmacokinetics of vismodegib in healthy female subjects of&#xD;
      non-childbearing potential. Subjects will be randomized to receive multiple oral doses of&#xD;
      vismodegib, alone or in combination with multiple oral doses of either rabeprazole,&#xD;
      itraconazole or fluconazole. Anticipated time on study treatment is up to 11 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative effect of rabeprazole on steady-state pharmacokinetics of vismodegib: Area under the concentration-time curve (AUC)/Steady-state concentration (Css)</measure>
    <time_frame>up to 12 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative effect of itraconazole on steady-state pharmacokinetics of vismodegib: Area under the concentration-time curve (AUC)/Steady-state concentration (Css)</measure>
    <time_frame>up to 12 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative effect of fluconazole on the steady-state pharmacokinetics of vismodegib: Area under the concentration-time curve (AUC)/Steady-state concentration (Css)</measure>
    <time_frame>up to 12 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>A: Vismodegib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Rabeprazole + Vismodegib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C: Itraconazole + Vismodegib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>D: Fluconazole + Vismodegib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluconazole</intervention_name>
    <description>Multiple oral doses</description>
    <arm_group_label>D: Fluconazole + Vismodegib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>itraconazole</intervention_name>
    <description>Multiple oral doses</description>
    <arm_group_label>C: Itraconazole + Vismodegib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rabeprazole</intervention_name>
    <description>Multiple oral doses</description>
    <arm_group_label>B: Rabeprazole + Vismodegib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vismodegib</intervention_name>
    <description>Multiple oral doses</description>
    <arm_group_label>A: Vismodegib</arm_group_label>
    <arm_group_label>B: Rabeprazole + Vismodegib</arm_group_label>
    <arm_group_label>C: Itraconazole + Vismodegib</arm_group_label>
    <arm_group_label>D: Fluconazole + Vismodegib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females of non-childbearing potential&#xD;
&#xD;
          -  Body mass index (BMI) 18 to 32 kg/m2, inclusive&#xD;
&#xD;
          -  In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination. 12-lead ECG, and vital signs&#xD;
&#xD;
          -  Clinical laboratory evaluations, complete blood count and urinalysis within the normal&#xD;
             range for the test laboratory, unless not deemed clinically significant by the&#xD;
             investigator&#xD;
&#xD;
          -  Negative test for drugs of abuse at screening and check-in (including alcohol)&#xD;
&#xD;
          -  Negative for hepatitis B, hepatitis C and HIV infection&#xD;
&#xD;
          -  Non-childbearing potential is defined as: non-pregnant, non-lactating, and either&#xD;
             postmenopausal for at least 1 year or surgically sterile (e.g. bilateral oophorectomy&#xD;
             and/or hysterectomy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant history or clinical evidence of any metabolic (including type 1 or 2&#xD;
             diabetes). allergic, dermatological, hepatic, renal, hematological, pulmonary,&#xD;
             cardiovascular, endocrine, GI (including gastric or duodenal ulcers),&#xD;
             Zollinger-Ellison syndrome, Barrett's esophagus, urological, neurological, or&#xD;
             psychiatric disorder&#xD;
&#xD;
          -  History of inflammatory arthritis&#xD;
&#xD;
          -  History of symptomatic hypotension&#xD;
&#xD;
          -  History of seizure disorders&#xD;
&#xD;
          -  History of bipolar or major depressive disorder&#xD;
&#xD;
          -  History of stomach or intestinal surgery or resection that would potentially alter&#xD;
             absorption and/or excretion of orally administered drugs (appendectomy, hernia repair,&#xD;
             and/or cholecystectomy will be allowed)&#xD;
&#xD;
          -  History of alcoholism or drug addiction within 1 year prior to check-in&#xD;
&#xD;
          -  Use of any tobacco- or nicotine-containing products within 6 months prior to check-in&#xD;
&#xD;
          -  Participation in any other investigational study drug or biological agent trial in&#xD;
             which receipt of investigational study drug occurred within 5 half-lives or 30 days,&#xD;
             whichever is longer, prior to check-in&#xD;
&#xD;
          -  Use of PPIs, H2-receptor antagonists, or antacids within 1 month prior to check-in&#xD;
&#xD;
          -  History of chronic PPI use (&gt; 30 days of continuous daily dosing) within 6 months of&#xD;
             check-in&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>January 17, 2013</study_first_submitted>
  <study_first_submitted_qc>January 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2013</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

